Published in Mol Cancer Ther on November 20, 2013
The yin and yang of kidney development and Wilms' tumors. Genes Dev (2015) 0.95
Energy metabolism in neuroblastoma and Wilms tumor. Transl Pediatr (2015) 0.86
The IGF signalling pathway in Wilms tumours--a report from the ENCCA Renal Tumours Biology-driven drug development workshop. Oncotarget (2014) 0.82
SIX2 Effects on Wilms Tumor Biology. Transl Oncol (2014) 0.82
Unusual association of non-anaplastic Wilms tumor and Cornelia de Lange syndrome: case report. BMC Cancer (2016) 0.75
High dose therapy for recurrent Wilms' tumor. Transl Pediatr (2014) 0.75
Activation of the Wnt/β-catenin pathway is common in wilms tumor, but rarely through β-catenin mutation and APC promoter methylation. Pediatr Surg Int (2016) 0.75
Mutations affecting segment number and polarity in Drosophila. Nature (1980) 18.72
Wnt/β-catenin signaling and disease. Cell (2012) 16.05
Intestinal polyposis in mice with a dominant stable mutation of the beta-catenin gene. EMBO J (1999) 10.82
Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome. Cell (1982) 9.29
Inactivation of the beta-catenin gene by Wnt1-Cre-mediated deletion results in dramatic brain malformation and failure of craniofacial development. Development (2001) 9.00
beta-Catenin controls hair follicle morphogenesis and stem cell differentiation in the skin. Cell (2001) 8.41
Epithelial transformation of metanephric mesenchyme in the developing kidney regulated by Wnt-4. Nature (1994) 6.57
Six2 defines and regulates a multipotent self-renewing nephron progenitor population throughout mammalian kidney development. Cell Stem Cell (2008) 5.76
Wilms tumor suppressor WTX negatively regulates WNT/beta-catenin signaling. Science (2007) 5.08
Lack of beta-catenin affects mouse development at gastrulation. Development (1995) 4.95
Wnt/beta-catenin signaling in cancer stemness and malignant behavior. Curr Opin Cell Biol (2007) 4.75
Deciphering the function of canonical Wnt signals in development and disease: conditional loss- and gain-of-function mutations of beta-catenin in mice. Genes Dev (2008) 4.38
An X chromosome gene, WTX, is commonly inactivated in Wilms tumor. Science (2007) 4.00
The many faces and functions of β-catenin. EMBO J (2012) 3.85
The Drosophila homolog of the mouse mammary oncogene int-1 is identical to the segment polarity gene wingless. Cell (1987) 3.78
Patterning a complex organ: branching morphogenesis and nephron segmentation in kidney development. Dev Cell (2010) 3.78
Relaxation of insulin-like growth factor II gene imprinting implicated in Wilms' tumour. Nature (1993) 3.24
Wnt/beta-catenin signaling regulates nephron induction during mouse kidney development. Development (2007) 2.92
Wnt-4 is a mesenchymal signal for epithelial transformation of metanephric mesenchyme in the developing kidney. Development (1998) 2.90
Loss of imprinting of IGF2 is linked to reduced expression and abnormal methylation of H19 in Wilms' tumour. Nat Genet (1994) 2.90
Wnt9b signaling regulates planar cell polarity and kidney tubule morphogenesis. Nat Genet (2009) 2.84
Wnt signaling in cancer. Cold Spring Harb Perspect Biol (2012) 2.75
Nephrogenic rests, nephroblastomatosis, and the pathogenesis of Wilms' tumor. Pediatr Pathol (1990) 2.68
Targeting Wnt signaling: can we safely eradicate cancer stem cells? Clin Cancer Res (2010) 2.67
Loss of imprinting of insulin-like growth factor-II (IGF2) gene in distinguishing specific biologic subtypes of Wilms tumor. J Natl Cancer Inst (2001) 2.02
Wilms' tumours: about tumour suppressor genes, an oncogene and a chameleon gene. Nat Rev Cancer (2011) 2.02
Mutational activation of the beta-catenin proto-oncogene is a common event in the development of Wilms' tumors. Cancer Res (1999) 1.93
Canonical Wnt9b signaling balances progenitor cell expansion and differentiation during kidney development. Development (2011) 1.92
Myogenesis in Wilms' tumors is associated with mutations of the WT1 gene and activation of Bcl-2 and the Wnt signaling pathway. Pediatr Dev Pathol (2004) 1.89
Frequent association of beta-catenin and WT1 mutations in Wilms tumors. Cancer Res (2000) 1.82
Wnt3a-mediated formation of phosphatidylinositol 4,5-bisphosphate regulates LRP6 phosphorylation. Science (2008) 1.81
Six2 and Wnt regulate self-renewal and commitment of nephron progenitors through shared gene regulatory networks. Dev Cell (2012) 1.75
CTNNB1 mutations and overexpression of Wnt/beta-catenin target genes in WT1-mutant Wilms' tumors. Am J Pathol (2004) 1.72
Drug discovery approaches to target Wnt signaling in cancer stem cells. Oncotarget (2010) 1.71
Lineage specification of parietal epithelial cells requires β-catenin/Wnt signaling. J Am Soc Nephrol (2011) 1.64
Wilms tumor genetics: mutations in WT1, WTX, and CTNNB1 account for only about one-third of tumors. Genes Chromosomes Cancer (2008) 1.62
Effect of the Wingless (wg1) mutation on wing and haltere development in Drosophila melanogaster. Dev Biol (1976) 1.57
A wt1-controlled chromatin switching mechanism underpins tissue-specific wnt4 activation and repression. Dev Cell (2011) 1.46
Targeting Wnt signaling in colon cancer stem cells. Clin Cancer Res (2010) 1.46
Development of an siRNA-based method for repressing specific genes in renal organ culture and its use to show that the Wt1 tumour suppressor is required for nephron differentiation. Hum Mol Genet (2003) 1.44
Glycogen synthase kinase-3 inactivation and stabilization of beta-catenin induce nephron differentiation in isolated mouse and rat kidney mesenchymes. J Am Soc Nephrol (2007) 1.44
β-catenin tyrosine 654 phosphorylation increases Wnt signalling and intestinal tumorigenesis. Gut (2011) 1.40
Nephrogenic rests and the pathogenesis of Wilms tumor: developmental and clinical considerations. Am J Med Genet (1998) 1.30
Wnt4 induces nephronic tubules in metanephric mesenchyme by a non-canonical mechanism. Dev Biol (2011) 1.27
Targeting the Wnt/β-catenin signaling pathway in human cancers. Expert Opin Ther Targets (2011) 1.25
Apc deficiency predisposes to renal carcinoma in the mouse. Oncogene (2005) 1.23
Clinically relevant subsets identified by gene expression patterns support a revised ontogenic model of Wilms tumor: a Children's Oncology Group Study. Neoplasia (2012) 1.19
Probing transcription-specific outputs of β-catenin in vivo. Genes Dev (2011) 1.18
Wt1 ablation and Igf2 upregulation in mice result in Wilms tumors with elevated ERK1/2 phosphorylation. J Clin Invest (2010) 1.17
Sustaining innovation and improvement in the treatment of childhood cancer: lessons from high-income countries. Lancet Oncol (2013) 1.17
The isolation and characterization of renal cancer initiating cells from human Wilms' tumour xenografts unveils new therapeutic targets. EMBO Mol Med (2012) 1.15
Sequential WT1 and CTNNB1 mutations and alterations of beta-catenin localisation in intralobar nephrogenic rests and associated Wilms tumours: two case studies. J Clin Pathol (2006) 1.11
Calcium/NFAT signalling promotes early nephrogenesis. Dev Biol (2011) 1.10
Two molecular subgroups of Wilms' tumors with or without WT1 mutations. Clin Cancer Res (2003) 1.06
Functional inactivation of the WTX gene is not a frequent event in Wilms' tumors. Oncogene (2008) 1.06
New avenues to target Wnt/β-catenin signaling. Drug Discov Today (2010) 1.03
Resistance or sensitivity of Wilms' tumor to anti-FZD7 antibody highlights the Wnt pathway as a possible therapeutic target. Oncogene (2011) 1.03
Canonical WNT signalling determines lineage specificity in Wilms tumour. Oncogene (2009) 1.00
A genome-wide association study identifies susceptibility loci for Wilms tumor. Nat Genet (2012) 0.97
WNT/beta-catenin pathway activation in Wilms tumors: a unifying mechanism with multiple entries? Genes Chromosomes Cancer (2009) 0.96
Stratification of Wilms tumor by genetic and epigenetic analysis. Oncotarget (2012) 0.95
WTX inactivation is a frequent, but late event in Wilms tumors without apparent clinical impact. Genes Chromosomes Cancer (2009) 0.91
Targeting embryonic signaling pathways in cancer therapy. Expert Opin Ther Targets (2012) 0.89
Temporal blastemal cell gene expression analysis in the kidney reveals new Wnt and related signaling pathway genes to be essential for Wilms' tumor onset. Cell Death Dis (2011) 0.86
Genetics of pediatric renal tumors. Pediatr Nephrol (2012) 0.85
Different CTNNB1 mutations as molecular genetic proof for the independent origin of four Wilms tumours in a patient with a novel germ line WT1 mutation. J Med Genet (2007) 0.80
The stem and roots of Wilms' tumours. EMBO Mol Med (2012) 0.78
Conditional expression of Lodavin, an avidin-tagged LDL receptor, for biotin-mediated applications in vivo. Genesis (2012) 0.76
Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet (2013) 8.24
SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. Nat Genet (2008) 5.93
Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res (2005) 5.70
Breast-cancer risk in families with mutations in PALB2. N Engl J Med (2014) 4.97
A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nat Genet (2010) 4.96
Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma. J Clin Oncol (2010) 4.93
Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst (2010) 4.54
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35
Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat Genet (2013) 3.81
Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet (2008) 3.41
Single-nucleotide polymorphisms inside microRNA target sites influence tumor susceptibility. Cancer Res (2010) 2.82
Wt1 is required for cardiovascular progenitor cell formation through transcriptional control of Snail and E-cadherin. Nat Genet (2009) 2.52
BRCA1 p.Val1688del is a deleterious mutation that recurs in breast and ovarian cancer families from Northeast Italy. J Clin Oncol (2008) 2.45
Immediate nephrectomy versus preoperative chemotherapy in the management of non-metastatic Wilms' tumour: results of a randomised trial (UKW3) by the UK Children's Cancer Study Group. Eur J Cancer (2006) 2.39
Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet (2013) 2.39
PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification. J Clin Oncol (2012) 2.29
Nephron sparing surgery (NSS) for unilateral wilms tumor (UWT): the SIOP 2001 experience. Pediatr Blood Cancer (2014) 2.28
Constitutional 11p15 abnormalities, including heritable imprinting center mutations, cause nonsyndromic Wilms tumor. Nat Genet (2008) 2.24
Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers. Am J Hum Genet (2013) 2.24
Pathology of ovarian cancers in BRCA1 and BRCA2 carriers. Clin Cancer Res (2004) 2.17
Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet (2009) 2.13
The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing. Clin Cancer Res (2011) 2.09
Different genetic features associated with colon and rectal carcinogenesis. Clin Cancer Res (2004) 1.99
Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev (2011) 1.99
Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Res (2010) 1.90
Determination of cancer risk associated with germ line BRCA1 missense variants by functional analysis. Cancer Res (2007) 1.89
Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk. PLoS Genet (2013) 1.88
Lin28 sustains early renal progenitors and induces Wilms tumor. Genes Dev (2014) 1.87
Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer. Oncogene (2004) 1.82
19p13.1 is a triple-negative-specific breast cancer susceptibility locus. Cancer Res (2012) 1.81
Frequent long-range epigenetic silencing of protocadherin gene clusters on chromosome 5q31 in Wilms' tumor. PLoS Genet (2009) 1.77
Prediction and assessment of splicing alterations: implications for clinical testing. Hum Mutat (2008) 1.73
In utero origin of t(8;21) AML1-ETO translocations in childhood acute myeloid leukemia. Blood (2002) 1.71
Verification of the susceptibility loci on 7p12.2, 10q21.2, and 14q11.2 in precursor B-cell acute lymphoblastic leukemia of childhood. Blood (2009) 1.64
ErbB4 modulates tubular cell polarity and lumen diameter during kidney development. J Am Soc Nephrol (2011) 1.61
Common genetic variants and modification of penetrance of BRCA2-associated breast cancer. PLoS Genet (2010) 1.56
Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association Consortium. Hum Mol Genet (2011) 1.56
Array CGH using whole genome amplification of fresh-frozen and formalin-fixed, paraffin-embedded tumor DNA. Genomics (2005) 1.52
Impact of biospecimens handling on biomarker research in breast cancer. BMC Cancer (2009) 1.51
Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet (2011) 1.51
A wt1-controlled chromatin switching mechanism underpins tissue-specific wnt4 activation and repression. Dev Cell (2011) 1.46
Evaluation of SNPs in miR-146a, miR196a2 and miR-499 as low-penetrance alleles in German and Italian familial breast cancer cases. Hum Mutat (2010) 1.45
Development of an siRNA-based method for repressing specific genes in renal organ culture and its use to show that the Wt1 tumour suppressor is required for nephron differentiation. Hum Mol Genet (2003) 1.44
Soluble epidermal growth factor receptor isoforms in non-small cell lung cancer tissue and in blood. Lung Cancer (2011) 1.43
Prevalence of the Y165C, G382D and 1395delGGA germline mutations of the MYH gene in Italian patients with adenomatous polyposis coli and colorectal adenomas. Int J Cancer (2004) 1.42
Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst (2010) 1.41
Malignant renal tumours incidence and survival in European children (1978-1997): report from the Automated Childhood Cancer Information System project. Eur J Cancer (2006) 1.40
Fine-scale mapping of the FGFR2 breast cancer risk locus: putative functional variants differentially bind FOXA1 and E2F1. Am J Hum Genet (2013) 1.39
Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers. Breast Cancer Res (2012) 1.38
Age at menarche and menopause and breast cancer risk in the International BRCA1/2 Carrier Cohort Study. Cancer Epidemiol Biomarkers Prev (2007) 1.36
Identification of human nephron progenitors capable of generation of kidney structures and functional repair of chronic renal disease. EMBO Mol Med (2013) 1.32
Improved clinical outcome in indolent B-cell lymphoma patients vaccinated with autologous tumor cells experiencing immunogenic death. Cancer Res (2010) 1.28
Acute multiple organ failure in adult mice deleted for the developmental regulator Wt1. PLoS Genet (2011) 1.27
11q13 is a susceptibility locus for hormone receptor positive breast cancer. Hum Mutat (2012) 1.26
Incidental carcinomas in prophylactic specimens in BRCA1 and BRCA2 germ-line mutation carriers, with emphasis on fallopian tube lesions: report of 6 cases and review of the literature. Am J Surg Pathol (2006) 1.26
Identification of MET and SRC activation in melanoma cell lines showing primary resistance to PLX4032. Neoplasia (2011) 1.26
Reproductive and hormonal factors, and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: results from the International BRCA1/2 Carrier Cohort Study. Cancer Epidemiol Biomarkers Prev (2009) 1.25
Relationship between MYCN copy number and expression in rhabdomyosarcomas and correlation with adverse prognosis in the alveolar subtype. J Clin Oncol (2005) 1.25
The ALCAM shedding by the metalloprotease ADAM17/TACE is involved in motility of ovarian carcinoma cells. Mol Cancer Res (2007) 1.25
Loss of the inactive X chromosome and replication of the active X in BRCA1-defective and wild-type breast cancer cells. Cancer Res (2005) 1.25
Role for amplification and expression of glypican-5 in rhabdomyosarcoma. Cancer Res (2007) 1.24
Confirmation of 5p12 as a susceptibility locus for progesterone-receptor-positive, lower grade breast cancer. Cancer Epidemiol Biomarkers Prev (2011) 1.23
Atypical epithelial proliferation in fallopian tubes in prophylactic salpingo-oophorectomy specimens from BRCA1 and BRCA2 germline mutation carriers. Int J Gynecol Pathol (2004) 1.22
Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Res (2011) 1.22
Cyclooxygenase-2 and platelet-derived growth factor receptors as potential targets in treating aggressive fibromatosis. Clin Cancer Res (2007) 1.21
Blastemal expression of type I insulin-like growth factor receptor in Wilms' tumors is driven by increased copy number and correlates with relapse. Cancer Res (2006) 1.21
A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity. Cancer Res (2012) 1.21
Incidence of and survival from Wilms' tumour in adults in Europe: data from the EUROCARE study. Eur J Cancer (2006) 1.18
Genomic imbalances in rhabdomyosarcoma cell lines affect expression of genes frequently altered in primary tumors: an approach to identify candidate genes involved in tumor development. Genes Chromosomes Cancer (2009) 1.18
Pharmacokinetics of dactinomycin in a pediatric patient population: a United Kingdom Children's Cancer Study Group Study. Clin Cancer Res (2005) 1.17
Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev (2012) 1.17
WT1 maintains adrenal-gonadal primordium identity and marks a population of AGP-like progenitors within the adrenal gland. Dev Cell (2013) 1.16
Bevacizumab for macular serous neuroretinal detachment in tilted disk syndrome. J Ophthalmol (2010) 1.14
Comparison of 6q25 breast cancer hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC). PLoS One (2012) 1.13
Interplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer. PLoS Biol (2011) 1.12
New policies to address the global burden of childhood cancers. Lancet Oncol (2013) 1.12
RET is constitutively activated by novel tandem mutations that alter the active site resulting in multiple endocrine neoplasia type 2B. Cancer Res (2006) 1.12
Whole exome sequencing suggests much of non-BRCA1/BRCA2 familial breast cancer is due to moderate and low penetrance susceptibility alleles. PLoS One (2013) 1.10
Frequency and heritability of WT1 mutations in nonsyndromic Wilms' tumor patients: a UK Children's Cancer Study Group Study. J Clin Oncol (2004) 1.09
Secretome compartment is a valuable source of biomarkers for cancer-relevant pathways. J Proteome Res (2011) 1.09
Effect of media portrayals of removal of children's tissue on UK tumour bank. BMJ (2005) 1.09
Alternately spliced WT1 antisense transcripts interact with WT1 sense RNA and show epigenetic and splicing defects in cancer. RNA (2007) 1.09
Amplification and overexpression of CACNA1E correlates with relapse in favorable histology Wilms' tumors. Clin Cancer Res (2006) 1.09
Dysregulation of ubiquitin homeostasis and β-catenin signaling promote spinal muscular atrophy. J Clin Invest (2014) 1.08
Second primary neoplasms in survivors of Wilms' tumour--a population-based cohort study from the British Childhood Cancer Survivor Study. Int J Cancer (2008) 1.08
Wilms' tumor with intracaval thrombus in the UK Children's Cancer Study Group UKW3 trial. J Pediatr Surg (2006) 1.06
SIOP PODC: clinical guidelines for the management of children with Wilms tumour in a low income setting. Pediatr Blood Cancer (2012) 1.04
Misbehaviour of XIST RNA in breast cancer cells. PLoS One (2009) 1.04
Hereditary leiomyomatosis and renal cell carcinoma: very early diagnosis of renal cancer in a paediatric patient. Fam Cancer (2010) 1.02
miRNA profiles as a predictor of chemoresponsiveness in Wilms' tumor blastema. PLoS One (2013) 1.02
Regulation of breast cancer response to chemotherapy by fibulin-1. Cancer Res (2007) 1.02
Mesoblastic nephroma: a report of the United Kingdom Children's Cancer and Leukaemia Group (CCLG). Pediatr Blood Cancer (2011) 1.02
Comparison of mRNA splicing assay protocols across multiple laboratories: recommendations for best practice in standardized clinical testing. Clin Chem (2013) 1.01
Molecular profiling reveals frequent gain of MYCN and anaplasia-specific loss of 4q and 14q in Wilms tumor. Genes Chromosomes Cancer (2011) 1.01
A human cell-based assay to evaluate the effects of alterations in the MLH1 mismatch repair gene. Cancer Res (2006) 1.01
A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46,450 cases and 42,461 controls from the breast cancer association consortium. Hum Mol Genet (2013) 1.00
90Y Labeling of monoclonal antibody MOv18 and preclinical validation for radioimmunotherapy of human ovarian carcinomas. Cancer Immunol Immunother (2005) 1.00